Anethole trithione for use in preventing, treating, and / or lessening acute radiation syndrome
Anethole trithione (AOL) addresses the limitations of current antioxidant drugs by stimulating DNA repair, effectively reducing unrepaired DNA damage and improving radiation protection outcomes.
Patent Information
- Application Number
- PCT/EP2026/064253
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Current antioxidant drugs for radiation protection, such as Amifostine, have limitations including a narrow therapeutic window and adverse side effects, and do not effectively reduce unrepaired DNA damage leading to cellular lethality.
Anethole trithione (AOL) or its structural analogs are used to stimulate DNA strand breaks repair by facilitating the nucleo shuttling of the ATM serine/threonine kinase, providing a pro-episkevic effect to prevent, treat, and lessen acute radiation syndrome.
AOL effectively reduces unrepaired DNA damage and stimulates repair, offering improved therapeutic potential with fewer side effects compared to existing drugs.
Smart Images

Figure IMGF000002_0001 
Figure IMGF000016_0001 
Figure IMGF000016_0002
Abstract
Description
ANETHOLE TRITHIONE FOR USE IN PREVENTING, TREATING, AND / OR LESSENING ACUTE RADIATION SYNDROMEFIELD OF INVENTION
[0001] The present invention relates to anethole trithione (AOL) or a structural analog thereof, for use in preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof.BACKGROUND OF INVENTION
[0002] The use of antioxidant drugs has been, and remains, the main approach in radiation protection research. Numerous antioxidants have been tested, including N-acetylcysteine (NAC) and oltipraz (OPZ), but the drug most widely used clinically and especially in radiotherapy is Ethyol® (Amifostine). Yet this drug, which is the only one authorized by the MDA, has never made its mark in radiotherapy due to its significant limitations, including a narrow therapeutic window, adverse side effects and limited efficacy in protecting normal tissues without interfering with tumor control. These drawbacks have prompted ongoing research into alternative radioprotective agents with improved therapeutic potential.
[0003] At the same time, radiobiologists have observed that, although the amount of radiation-induced DNA damage is reduced by antioxidants, the amount of unrepaired DNA damage, which determines cellular lethality (toxicity), is not necessarily reduced by the action of antioxidants. The development of drugs that stimulate repair (“episkeve” in Greek, i.e., pro-episkevic drugs) is therefore another area of research in radiation protection (Restier-Verlet et al., Biomolecules; 2023).
[0004] The Inventors surprisingly demonstrated that AOL has pro-episkevic effect, and shows AOL’s superiority in radiation protection. Attesting that AOL could be used for preventing, treating, and / or lessening acute radiation syndrome.SUMMARY
[0005] This invention thus relates to Anethole trithione (AOL) or a structural analog thereof, for use in preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof.
[0006] In some embodiments, the subject has been exposed to ionizing radiation.
[0007] In some embodiments, the subject has been exposed to ionizing radiation of more than 2 Gy.
[0008] In some embodiments, the structural analog of AOL is a compound of formula (I):TV>=(R4R5wherein:X represents S, O or NHOH; preferably X is S or O; more preferably, X is S;Y represents CH, C or N; preferably Y is CH or N; more preferably Y is CH;R1, R2, R4and R5each independently represent hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl;R3is methoxy or hydroxy; or R3and R2together with the carbon atoms to which they are attached form a 5-membered heteroaryl moiety wherein -R3-R2- represents -A-CR6=B- or -B=CR6-A-; wherein:A reprsents O, S or NR7; wherein R7represents hydrogen, Ci-Cs alkyl or alkyloxycarbonyl;B represents CH or N; andR6represents hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxy alkyl.
[0009] This invention also relates to a pharmaceutical composition for use in preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof, comprising Anethole trithione (AOL) or a structural analog thereof, as described herein, and at least one pharmaceutically acceptable excipient.
[0010] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition, as described herein, is to be administered before, concomitantly with or after at least one other therapeutic agent, preferably the at least one other therapeutic agent is selected from the group of: N-acetylcysteine, oltipraz, and amifostine.
[0011] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition, as described herein, is to be administered before the radiation exposure.
[0012] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition, as described herein, is to be administered intravenously.
[0013] In some embodiments, the acute radiation syndrome is selected from (a) hematopoietic acute radiation syndrome, (b) gastrointestinal acute radiation syndrome, (c) cutaneous acute radiation syndrome, (d) central nervous system (CNS) acute radiation syndrome, (e) hematopoietic, gastrointestinal, cutaneous or neurovascular subsyndrome of acute radiation syndrome, (f) cardiovascular (CV) acute radiation syndrome, or (g) pulmonary dysfunction acute radiation syndrome.DEFINITIONS
[0014] In the present invention, the following terms have the following meanings:
[0015] “about”, preceding a figure, means plus or less 10% of the value of said figure.
[0016] “Acute Radiation Syndrome” (ARS) refers to a collection of health effects that are caused by being exposed to high amounts of ionizing radiation in a short period of time. Symptoms can start within some ten minutes (10 min) of exposure, and can last for several months. Early symptoms are usually nausea, vomiting and loss of appetite. In the following hours or weeks, initial symptoms may appear to improve, before the development of additional symptoms, after which either recovery or death follow.
[0017] “alkoxy” as used herein by itself or as part of another substituent refers to a group -O-alkyl wherein alkyl is as herein defined.
[0018] “alkyl” as used herein by itself or as part of another substituent refers to a hydrocarbyl radical of formula CnH2n+l wherein n is a number greater than or equal to 1. Generally, alkyl groups of this invention comprise from 1 to 8 carbon atoms, preferably from 1 to 6 carbon atoms, more preferably from 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms. Alkyl groups may be linear or branched. Suitable alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl.
[0019] “alkylamino” as used herein by itself or as part of another substituent refers to a group -NH-alkyl wherein alkyl is as herein defined.
[0020] “alkyloxycarbonyl” as used herein by itself or as part of another substituent refers to a group -C(=O)-O-alkyl, wherein alkyl is as herein defined. A preferred alkyloxycarbonyl group is methyloxycarbonyl.
[0021] “alkylsulfonyl” as used herein by itself or as part of another substituent refers to a group -SO2-alkyl wherein alkyl is as herein defined.
[0022] “amino” as used herein refers to a group -NH2.
[0023] “aminoalkyl” as used herein by itself or as part of another substituent refers to a group -alkyl-NH2 wherein alkyl is as herein defined.
[0024] “aminosulfonyl” as used herein by itself or as part of another substituent refers to a group -SO2-NH2.
[0025] “aryl” as used herein by itself or as part of another substituent refers to a polyunsaturated, aromatic hydrocarbyl group having a single ring (i.e., phenyl) or multiple aromatic rings fused together (e.g., naphtyl), typically containing 5 to 12 atoms; preferably 6 to 10. Non-limiting examples of aryl comprise phenyl, naphthalenyl.
[0026] “The becquerel (Bq)” is the International System of Units (SI) unit of radioactivity. It represents the rate of radioactive decay and corresponds to one nuclear disintegration per second emitted by a radioactive source. Thus, a radioactive source having an activity of 1 Bq undergoes, on average, one nuclear disintegration per second. The terabecquerel (TBq) is a derived unit of radioactivity equal to 1012becquerels, i.e., 1,000,000,000,000 disintegrations per second. This unit is typically used to express high levels of activity associated with radioactive sources. A person skilled in the art will understand how to convert the activity of a radioactive source, expressed in terabecquerels (TBq), into an absorbed dose expressed in grays (Gy).
[0027] “bio-isosteres” as used herein refers to compounds or groups that possess nearequal molecular shapes and volumes, approximately the same distribution of electrons, and which exhibit similar physical properties and similar biological activities.
[0028] “carboxy” as used herein refers to a group -COOH.
[0029] “carboxyalkyl” as used herein by itself or as part of another substituent refers to a group -alkyl-COOH wherein alkyl is as herein defined.
[0030] “degree of substitution” (“n” or DS) of a polymer, i.e., a substituted cyclodextrin, is the average number of substituent groups attached per base unit or per monomeric unit. In one embodiment, the “degree of substitution” is expressed as degree of molar substitution (MS). In one embodiment, the DS or MS of a mono- or multisubstituted cyclodextrin is indicated as a range of values. In one embodiment, the DS orMS of a mono- or multi- substituted cyclodextrin is indicated as the median of the range of values measured in the population of cyclodextrins in the sample.
[0031] “Gray” (symbole Gy) is the SI unit absorbed dose and is defined as the absorption of one joule of energy, in the form of ionizing radiation, per kilogram of matter.
[0032] “halo” or “halogen” means fluoro, chloro, bromo, or iodo.
[0033] “haloalkyl” itself or as part of another substituent, refers to an alkyl radical as herein defined wherein one or more hydrogens are replaced with a halogen as herein defined. Non-limiting examples of haloalkyl include fluoromethyl, difluoromethyl and trifluoromethyl.
[0034] “heteroaryl” as used herein by itself or as part of another substituent refers to an aryl group as herein defined wherein at least one carbon atom is replaced with a heteroatom. In other words, it refers to 5 to 12 carbon-atom aromatic single rings or ring systems containing 2 rings which are fused together, typically containing 5 to 6 atoms; in which one or more carbon atoms is replaced by oxygen, nitrogen and / or sulfur atoms where the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized. Non-limiting examples of such heteroaryl, include: oxazolyl, thiazolyl, imidazolyl, furanyl and pyrrolyl.
[0035] “Ionizing radiation” refers to any type of radiation that has enough energy to remove tightly bound electrons from atoms, thus creating ions. This process is known as ionization. Ionizing radiation is a form of energy that can come from radioactive materials, cosmic rays, and certain man-made sources like X-ray machines. There are several types of ionizing radiation, including: alpha particles, beta particles, gamma rays and X-rays, and neutrons.
[0036] “pharmaceutically acceptable excipient” refers to an excipient that does not produce an adverse, allergic or other untoward reaction when administered to an animal, preferably a human. It includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by regulatory offices, such as, e.g., FDA Office or EMA.
[0037] “pro-episkevic” refers to a drug that stimulate DNA strand breaks repair by facilitating the nucleo shuttling of the ATM serine / threonine kinase (ATM protein), also called Ataxia-telangiectasia mutated protein.
[0038] “nitrooxyalkyl” as used herein by itself or as part of another substituent refers to a group -alkyl-ONO2 wherein alkyl is as herein defined.
[0039] “salt” of the compounds of the invention is used herein to describe the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Non-limiting examples include the acetate, trifluoroacetate, adipate, aspartate, benzoate, besylate, bicarbonate / carbonate, bisulphate / sulphate, borate, tetrafluoroborate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate salts. Suitable base salts are formed from bases which form non-toxic salts. Non-limiting examples include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, 2-(diethylamino)ethanol, ethanolamine, morpholine, 4-(2-hydroxyethyl)morpholine and zinc salts. Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. Preferred, pharmaceutically acceptable salts include hydrochloride / chloride, hydrobromide / bromide, bisulphate / sulphate, nitrate, citrate, and acetate.
[0040] “solvate” is used herein to describe a compound in this invention that contains stoichiometric or sub- stoichiometric amounts of one or more pharmaceutically acceptable solvent molecule such as ethanol or water, “hydrate” refers to when said solvent is water.
[0041] “subject” refers to an animal, including a human. In the sense of the present invention, a subject may be a patient, i.e., a person receiving medical attention, undergoing or having underwent a medical treatment, or monitored for the development of a disease. In some embodiments, the animal could probably be typically a warmblooded animal, preferably a mammal. The term “mammal” refers here to any mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is a primate, preferably a human. In one embodiment, the subject is a “patient” as defined herein. In one embodiment, the subject is an adult (for example a subject above the age of 18). In one embodiment, the subject is a child (for example a subject below the age of 18). In one embodiment, the subject is a male. In one embodiment, the subject is a female. In one embodiment, the subject is affected, preferably is diagnosed with an acute radiation syndrome. In one embodiment, the subject has been exposed to ionizing radiation.
[0042] “tautomer” refers to organic compounds that are interconvertible by a chemical reaction called tautomerization. Said chemical reaction involves the migration of a hydrogen atom or proton, accompanied by a switch of a single bond and adjacent double bond.
[0043] “therapeutically effective amount” means level or amount of agent that is aimed at, without causing significant negative or adverse side effects to the target, (1) delaying or preventing the onset of a disease, disorder, or condition related to acute radiation syndrome; (2) slowing down or stopping the progression, aggravation, or deterioration of one or more symptoms of the disease, disorder, or condition related to acute radiation syndrome; (3) bringing about ameliorations of the symptoms of the disease, disorder, or condition related to acute radiation syndrome; (4) reducing the severity or incidence of the disease, disorder, or condition related to acute radiation syndrome; or (5) curing the disease, disorder, or condition related to acute radiation syndrome. A therapeutically effective amount may be administered prior to the onset of the disease, disorder, or condition related to acute radiation syndrome, for a prophylactic or preventive action. Alternatively, or additionally, the therapeutically effective amountmay be administered after initiation of the disease, disorder, or condition related to acute radiation syndrome, for a therapeutic action.
[0044] ‘ treating’ ’ , ‘ treatment’ ’ or ‘ ‘alleviation” refer to both therapeutic treatment and prophylactic or preventative measures; wherein the object is to prevent or slow down the targeted pathologic condition or disease. Those in need of treatment include those already with the disease as well as those prone to have the disease or those in whom the disease is to be prevented. “Lessening” refers more specifically to reducing, attenuating or limiting the severity, extent, duration or adverse effects of a targeted pathologic condition or disease, including one or more symptoms or complications associated therewith, without necessarily providing a complete cure thereof.DETAILED DESCRIPTION
[0045] This invention relates to anethole trithione (AOL) or a structural analog thereof, for use in preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof.
[0046] In some embodiments, the subject has been exposed to radiation.
[0047] In some embodiments, the subject has been exposed to ionizing radiation.
[0048] In some embodiments, the ionizing radiation is selected from the group consisting of: alpha particles, beta particles, gamma rays, X rays, neutron, and a combination thereof.
[0049] In some embodiments, the ionizing radiation comprises or consists of gamma rays.
[0050] In some embodiments, the ionizing radiation comprises radiation emitted from a cesium- 137 source.
[0051] In some embodiments, the subject has been exposed to at least 2 Gy, at least 3 Gy, at least 4 Gy, at least 5 Gy, at least 6 Gy, at least 7 Gy, at least 8 Gy, at least 9 Gy, atleast 10 Gy, at least 11 Gy, at least 12 Gy, at least 13 Gy, at least 14 Gy, at least 15 Gy, at least 16 Gy, at least 17 Gy, at least 18 Gy, at least 19 Gy, at least 20 Gy, at least 21 Gy, at least 22 Gy, at least 23 Gy, at least 24 Gy, at least 25 Gy, at least 26 Gy, at least 27 Gy, at least 28 Gy, at least 29 Gy, at least 30 Gy, at least 31 Gy, at least 32 Gy, at least 33 Gy, at least 34 Gy, at least 35 Gy, at least 36 Gy, at least 37 Gy, at least 38 Gy, at least 39 Gy, at least 40 Gy, at least 41 Gy, at least 42 Gy, at least 43 Gy, at least 44 Gy, at least 45 Gy, at least 46 Gy, at least 47 Gy, at least 48 Gy, at least 49 Gy, or at least 50 Gy; preferably at least 2 Gy or at least 8 Gy.
[0052] In some embodiments, the subject has been exposed to more than 2 Gy, more than 3 Gy, more than 4 Gy, more than 5 Gy, more than 6 Gy, more than 7 Gy, more than 8 Gy, more than 9 Gy, more than 10 Gy, more than 11 Gy, more than 12 Gy, more than 13 Gy, more than 14 Gy, more than 15 Gy, more than 16 Gy, more than 17 Gy, more than 18 Gy, more than 19 Gy, more than 20 Gy, more than 21 Gy, more than 22 Gy, more than 23 Gy, more than 24 Gy, more than 25 Gy, more than 26 Gy, more than 27 Gy, more than 28 Gy, more than 29 Gy, more than 30 Gy, more than 31 Gy, more than 32 Gy, more than 33 Gy, more than 34 Gy, more than 35 Gy, more than 36 Gy, more than 37 Gy, more than 38 Gy, more than 39 Gy, more than 40 Gy, more than 41 Gy, more than 42 Gy, more than 43 Gy, more than 44 Gy, more than 45 Gy, more than 46 Gy, more than 47 Gy, more than 48 Gy, more than 49 Gy, or more than 50 Gy; more preferably more than 2 Gy or more than 8 Gy.
[0053] In some embodiments, the subject has been exposed from about 2 Gy to about 50 Gy, from about 2 Gy to about 40 Gy, from about 2 Gy to about 30 Gy, from about 2 Gy to about 20 Gy, from about 2 Gy to about 12 Gy, from about 2 Gy to about 11 Gy, from about 2 Gy to about 10 Gy, 3 Gy to about 50 Gy, from about 3 Gy to about 40 Gy, from about 3 Gy to about 30 Gy, from about 3 Gy to about 20 Gy, from about 3 Gy to about 12 Gy, from about 3 Gy to about 11 Gy, from about 3 Gy to about 10 Gy, from about 4 Gy to about 50 Gy, from about 4 Gy to about 40 Gy, from about 4 Gy to about 30 Gy, from about 4 Gy to about 20 Gy, from about 4 Gy to about 12 Gy, from about 4 Gy to about 11 Gy, from about 4 Gy to about 10 Gy, from about 5 Gy to about 50 Gy, from about 5 Gy to about 40 Gy, from about 5 Gy to about 30 Gy, from about 5 Gy to about20 Gy, from about 5 Gy to about 12 Gy, from about 5 Gy to about 11 Gy, from about 5 Gy to about 10 Gy, from about 6 Gy to about 50 Gy, from about 6 Gy to about 40 Gy, from about 6 Gy to about 30 Gy, from about 6 Gy to about 20 Gy, from about 6 Gy to about 12 Gy, from about 6 Gy to about 11 Gy, from about 6 Gy to about 10 Gy, from about 7 Gy to about 50 Gy, from about 7 Gy to about 40 Gy, from about 7 Gy to about 30 Gy, from about 7 Gy to about 20 Gy, from about 7 Gy to about 12 Gy, from about 7 Gy to about 11 Gy, from about 7 Gy to about 10 Gy, from about 8 Gy to about 50 Gy, from about 8 Gy to about 40 Gy, from about 8 Gy to about 30 Gy, from about 8 Gy to about 20 Gy, from about 8 Gy to about 12 Gy, from about 8 Gy to about 11 Gy, from about 8 Gy to about 10 Gy, from about 9 Gy to about 50 Gy, from about 9 Gy to about 40 Gy, from about 9 Gy to about 30 Gy, from about 9 Gy to about 20 Gy, from about 9 Gy to about 12 Gy, from about 9 Gy to about 11 Gy, from about 9 Gy to about 10 Gy, from about 10 Gy to about 50 Gy, from about 10 Gy to about 40 Gy, from about 10 Gy to about 30 Gy, from about 10 Gy to about 20 Gy, from about 10 Gy to about 12 Gy, and from about 10 Gy to about 11 Gy, preferably from about 2 Gy to about 12 Gy, from about 2 Gy to about 10 Gy, from about 2 Gy to about 8 Gy, from about 3 Gy to about 12 Gy, from about 3 Gy to about 10 Gy and from about 3 Gy to about 8 Gy.
[0054] In some embodiments, the subject has been exposed from about 2 Gy to about 12 Gy, from about 2 Gy to about 11 Gy, from about 2 Gy to about 10 Gy, from about 3 Gy to about 12 Gy, from about 3 Gy to about 11 Gy, from about 3 Gy to about 10 Gy, from about 4 Gy to about 10 Gy, from about 5 Gy to about 10 Gy, from about 6 Gy to about 10 Gy, from about 7 Gy to about 10 Gy, from about 8 Gy to about 10 Gy, from about 9 Gy to about 10 Gy, from about 10 Gy to about 15 Gy, from about 10 Gy to about 20 Gy, from about 10 Gy to about 25 Gy, from about 10 Gy to about 30 Gy, from about 10 Gy to about 35 Gy, from about 10 Gy to about 40 Gy, from about 10 Gy to about 45 Gy, and from about 10 Gy to about 50 Gy.
[0055] In some embodiments, the subject has been exposed to at most 8 Gy, at most 10 Gy, at most 12 Gy, at most 15 Gy, at most 20 Gy, at most 25 Gy, at most 30 Gy, at most 35 Gy, at most 40 Gy, at most 45 Gy, or at most 50 Gy, preferably at most 10 Gy.
[0056] In some embodiments, the subject has been exposed to about 2 Gy, to about 3 Gy, to about 4 Gy, to about 4 Gy, to about 5 Gy, to about 6 Gy, to about 7 Gy, to about 8 Gy, to about 9 Gy, to about 10 Gy, to about 11 Gy, to about 12 Gy, to about 13 Gy, to about 14 Gy, to about 15 Gy, to about 16 Gy, to about 17 Gy, to about 18 Gy, to about 19 Gy, to about 20 Gy, to about 21 Gy, to about 22 Gy, to about 23 Gy, to about 24 Gy, to about 25 Gy, to about 26 Gy, to about 27 Gy, to about 28 Gy, to about 29 Gy, to about 30 Gy, to about 31 Gy, to about 32 Gy, to about 33 Gy, to about 34 Gy, to about 35 Gy, to about 36 Gy, to about 37 Gy, to about 38 Gy, to about 39 Gy, to about 40 Gy, to about 41 Gy, to about 42 Gy, to about 43 Gy, to about 44 Gy, to about 45 Gy, to about 46 Gy, to about 47 Gy, to about 48 Gy, to about 49 Gy or to about 50 Gy; preferably to about 5 Gy, to about 6 Gy, to about 7 Gy, to about 8 Gy, to about 9 Gy, to about 10 Gy, to about 11 Gy, to about 12 Gy; and more preferably to about 5 Gy, to about 6 Gy, to about 7 Gy, to about 8 Gy.
[0057] In some embodiments, the subject has been exposed to about 8,1 Gy.
[0058] In some embodiments, the source of irradiation is selected from the group consisting of: alpha particles, beta particles, gamma rays, X rays, neutron, and a combination thereof.
[0059] In some embodiments, the source of irradiation comprises or consists of gamma rays.
[0060] In some embodiments, the source of irradiation comprises radiation emitted from a cesium- 137 source.
[0061] In some embodiments, the source of irradiation may be selected from the group consisting of: an irradiator, a nuclear reactor and an electron beam generator. In some embodiments, the source of irradiation may be selected from the group consisting of: a nuclear reactor core meltdown, a criticality accident, a nuclear explosion (such as nuclear weapon explosion), a radiological dispersal device, and accidental exposure to unshielded activity radioactive sources (more preferably high- activity radioactive sources).
[0062] In some embodiments, the subject has been exposed to a source of irradiation having a total activity of from about 150 TBq to about 220 TBq, from about 155 TBq to about 215 TBq, from about 160 TBq to about 210 TBq, from about 170 TBq to about 200 TBq, from about 170 TBq to about 190 TBq or from about 175 TBq to about 185 TBq.
[0063] In some embodiments, the subject has been exposed to a source of irradiation having a total activity of about 110 TBq, to about 120 TBq, to about 130 TBq, to about 140 TBq, to about 150 TBq, to about 160 TBq, to about 170 TBq, to about 180 TBq, to about 190 TBq, to about 200 TBq, to about 210 TBq or to about 220 TBq.
[0064] In some embodiments, the subject has been exposed to a source of irradiation having a total activity of about 120 TBq, of about 130 TBq, of about 140 TBq, of about 150 TBq, of about 160 TBq, of about 170 TBq, of about 180 TBq, of about 190 TBq, of about 200 TBq, of about 210 TBq, of about 220 TBq, of about 230 TBq or of about 240 TBq.
[0065] In some embodiments, the subject has been exposed to a source of irradiation having a total activity of about 120 TBq, of about 130 TBq, of about 140 TBq, of about 150 TBq, of about 160 TBq, of about 170 TBq, of about 180 TBq, of about 190 TBq, of about 200 TBq, of about 210 TBq, of about 220 TBq, of about 230 TBq or of about 240 TBq.
[0066] In some embodiments, the subject has been exposed to a source of irradiation having a total activity of at least about 120 TBq, at least about 130 TBq, at least about 140 TBq, at least about 150 TBq, at least about 160 TBq, at least about 170 TBq, at least about 180 TBq, at least about 190 TBq, at least about 200 TBq, at least about 210 TBq, at least about 220 TBq, at least about 230 TBq, or at least about 240 TBq.
[0067] In some embodiments, , the subject has been exposed to a source of irradiation having a total activity of at most about 120 TBq, of at most about 130 TBq, of at most about 140 TBq, at most about 150 TBq, at most about 160 TBq, at most about 170 TBq, at most about 180 TBq, at most about 190 TBq, at most about 200 TBq, at most about 210 TBq, at most about 220 TBq, at most about 230 TBq, or at most about 240 TBq.
[0068] In some embodiments, the subject is exposed to a source of irradiation at a dose rate ranging from about 0.5 Gy / min to about 1.5 Gy / min, from about 0.6 Gy / min to about 1.4 Gy / min, from about 0.7 Gy / min to about 1.3 Gy / min, from about 0.8 Gy / min to about 1.2 Gy / min, from about 0.9 Gy / min to about 1.1 Gy / min.
[0069] In some embodiments, the subject is exposed to a source of irradiation at a dose rate of about 0.5 Gy / min, of about 0.6 Gy / min, of about 0.7 Gy / min, of about 0.8 Gy / min, of about 0.9 Gy / min, of about 1 Gy / min, of about 1.1 Gy / min, of about 1.2 Gy / min, of about 1.3 Gy / min, of about 1.4 Gy / min or of about 1.5 Gy / min.
[0070] In some embodiments, the subject is exposed to a source of irradiation at a dose rate of at least about 0.5 Gy / min, of at least about 0.6 Gy / min, of at least about 0.7 Gy / min, of at least about 0.8 Gy / min, of at least about 0.9 Gy / min, of at least about 1 Gy / min, of at least about 1.1 Gy / min, of at least about 1.2 Gy / min, of at least about 1.3 Gy / min, of at least about 1.4 Gy / min or of at least about 1.5 Gy / min.
[0071] In some embodiments, the subject is exposed to a source of irradiation at a dose rate of at most about 0.5 Gy / min, of at most about 0.6 Gy / min, of at most about 0.7 Gy / min, of at most about 0.8 Gy / min, of at most about 0.9 Gy / min, of at most about 1 Gy / min, of at most about 1.1 Gy / min, of at most about 1.2 Gy / min, of at most about 1.3 Gy / min, of at most about 1.4 Gy / min or of at most about 1.5 Gy / min.
[0072] In some embodiments, the subject has been exposed to radiation throughout the entire body.
[0073] In some embodiments, the subject has been exposed to radiation throughout the total body irradiation.
[0074] In some embodiments, the subject has been exposed to radiation throughout a part of the body.
[0075] In some embodiments, AOL or the structural analog thereof, is administered to the subject at a dose of about 5 mg / kg, about 10 mg / kg, about 20 mg / kg, about 30 mg / kg, about 40 mg / kg, or about 50 mg / kg.
[0076] In some embodiments, AOL or the structural analog thereof, is administered to the subject at a dose from about 5 mg / kg to about 50 mg / kg, from about 10 mg / kg to about 40 mg / kg or from about 20 mg / kg to about 30 mg / kg.
[0077] In some embodiments, AOL or the structural analog thereof, is administered to the subject at a dose of about 5 mg / kg, of about 10 mg / kg, of about 20 mg / kg, of about 30 mg / kg, of about 40 mg / kg or of about 50 mg / kg.
[0078] In some embodiments, AOL or the structural analog thereof, is administered to the subject at a dose of at least about 5 mg / kg, of at least about 10 mg / kg, of at least about 20 mg / kg, of at least about 30 mg / kg, of at least about 40 mg / kg or of at least about 50 mg / kg.
[0079] In some embodiments, AOL or the structural analog thereof, is administered to the subject at a dose of at most about 5 mg / kg, of at most about 10 mg / kg, of at most about 20 mg / kg, of at most about 30 mg / kg, of at most about 40 mg / kg or of at most about 50 mg / kg.
[0080] In some embodiments, the subject has been exposed to radiation throughout a part of the body, when said subject has been exposed to more than 12 Gy.
[0081] In some embodiments, AOL or the structural analog thereof induces the diffusion of the ATM protein into the nucleus to stimulate DNA damage repair.
[0082] In some embodiments, AOL or the structural analog thereof facilitates and / or accelerates the diffusion of the ATM protein into the nucleus to stimulate DNA damage repair.
[0083] In some embodiments, AOL or the structural analog thereof has pro-episkevic effect.
[0084] Anethole trithione corresponds to 5-(4-methoxyphenyl)-377- 1 ,2-dithiole-3-thione (AOL), registered under CAS number 532-11-6 and of formula:
[0085] In one embodiment, the structural analog of the invention is a compound of formula (I)I2R1Xor a pharmaceutically acceptable tautomer, salt or solvate thereof wherein:X represents S, O or NHOH; preferably X is S or O; more preferably, X is S; Y represents CH, C or N; preferably Y is CH or N; more preferably Y is CH; R1, R2, R4and R5each independently represent hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl;R3is hydroxy or methoxy; or R3and R2together with the carbon atoms to which they are attached form a 5-membered heteroaryl moiety wherein -R3-R2- represents-A-CR6=B- or -B=CR6-A-; wherein:A represents O, S or NR7; wherein R7represents hydrogen, Ci-Cs alkyl or alkyloxycarbonyl;B represents CH or N; andR6represents hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl.
[0086] According to a preferred embodiment, in formula (I):X represents S, O or NHOH; preferably X is S;Y represents CH, C or N; preferably Y is CH;R1, R2, R4and R5each independently represent hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl; preferably R1, R2, R4and R5represent hydrogen;R3is hydroxy or methoxy; or R3and R2together with the carbon atoms to which they are attached form a 5-membered heteroaryl moiety wherein -R3-R2- represents-A-CR6=B-; whereinA represents O, S or NR7; wherein R7represents hydrogen or Ci-Cs alkyl group;B represents CH or N; andR6represents hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl.
[0087] According to a preferred embodiment, X represents S. According to another preferred embodiment, X represents O. According to a preferred embodiment, Y represents CH. According to another preferred embodiment, Y represents N.
[0088] According to a preferred embodiment, R3represents methoxy. In another preferred embodiment, R3represents hydroxy.
[0089] According to a preferred embodiment, R3and R2together with the carbon atoms to which they are attached form a 5-membered heteroaryl moiety, wherein - R3- R2-represents -A-CR6=B-; wherein:A represents O, S or NR7; wherein R7represents hydrogen, C1-C8 alkyl or alkyloxycarbonyl; preferably R7represents hydrogen or alkyloxycarbonyl;B represents CH or N; andR6represents hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl; preferably R6represents hydrogen or hydroxyl.More preferably, -R3-R2- represents -O-C(OH)=N- or -N(COOMe)-CH=CH-, more preferably -R3-R2- represents -O-C(OH)=N-.
[0090] According to another preferred embodiment, R3and R2together with the carbon atoms to which they are attached form a 5-membered heteroaryl moiety wherein -R3-R2-represents -B=CR6-A-; whereinA represents O, S or NR7; wherein R7represents hydrogen, C1-C8 alkyl or alkyloxycarbonyl; preferably R7 represents hydrogen or alkyloxycarbonyl;B represents CH or N; andR6represents hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl; preferably R6 represents hydrogen or hydroxyl.More preferably, -R3-R2- represents -N=C(OH)-S-.
[0091] According to a preferred embodiment, the structural analog of the invention, is a compound of formula (I’)or a pharmaceutically acceptable tautomer, salt or solvate thereof wherein:X represents S, O or NHOH; preferably X is S or O; more preferably, X is S; Y represents CH, C or N; preferably Y is CH or N; more preferably Y is CH; R1, R4and R5each independently represent hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl;R2’ and R3’ together with the carbon atoms to which they are attached form a 5-membered heteroaryl moiety wherein -R3’-R2’- represents -A-CR6=B- or -B=CR6-A-; wherein:A represents O, S or NR7; wherein R7represents hydrogen, Ci-Cs alkyl or alkyloxycarbonyl;B represents CH or N; andR6represents hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl.
[0092] According to a preferred embodiment, the structural analog of the invention is a compound of formula (II)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, Y, R1, R4, R5, R6, A and B are as defined in formula (I).
[0093] According to one embodiment, in formula (II):X represents S, O or NHOH; preferably X is S;Y represents CH, C or N; preferably Y is CH;A represents O, S or NR7; wherein R7represents hydrogen or Ci-Cs alkyl group;B represent CH or N;R1, R4and R5each independently represent hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl;R6represents hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxy alkyl.
[0094] According to a preferred embodiment, compounds of formula (II) are of formulae (Ila) or (lib)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, Y, A, B, R1, R4, R5and R6are as defined above.
[0095] In a preferred embodiment, the structural analog of the invention is of formula (Ha).
[0096] According to a preferred embodiment, compound of formula (Ila) is of formulae (IIa-1) or (IIa-2)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, A, B, R1, R4, R5and R6are as defined above.
[0097] In a preferred embodiment, the structural analog of the invention is of formula (IIa-1). In another preferred embodiment, the structural analog of the invention is of formula (IIa-2).
[0098] According to a preferred embodiment, compound of formula (IIa-1) is of formulae (Ila-T), (IIa-1”) or (IIa-1’”)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein A, B, R1, R4, R5and R6are as defined above.
[0099] In a preferred embodiment, the structural analog of the invention is of formula (Ila- 1’ ) or (Ila- 1’ ’ ), more preferably of formula (Ila- 1’ ) .
[0100] According to a preferred embodiment, compound of formula (IIa-2) is of formulae (IIa-2’), (IIa-2”) or (IIa-2’”)R4(IIa-2’) (IIa-2”) (IIa-2’”) or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein A, B, R1, R4, R5and R6are as defined above.
[0101] In a preferred embodiment, the structural analog of the invention is of formula (IIa-2’) or (IIa-2”).
[0102] According to a preferred embodiment, compound of formula (IIa-1) and (IIa-2) is of formulae (Ila-la), (Ila-lb), (Ila-lc), (Ila-ld), (Ila-le), (IIa-2a), (IIa-2b), (IIa-2c), (Ila- 2d) or (IIa-2e)(Ila- la) (Ila-lc)(IIa-2a) (IIa-2b) (Ila- 2c)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, R1, R4, R5, R6and R7are as defined above.
[0103] In a preferred embodiment, the structural analog of the invention is of formula (Ila-la), (Ila-lb), (Ila-le), (IIa-2a), (Ila- 2b) or (IIa-2e), more preferably of formula (Ila-la) or (Ila-le); more preferably of formula (Ila- la).
[0104] According to a preferred embodiment, compound of formula (lib) is of formulae (lib’), (lib”) and (lib’”)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein A, B, R1, R4, R5and R6are as defined above.
[0105] According to a preferred embodiment, compound of formula (lib) is of formulae (IIb-1), (IIb-2), (IIb-3), (IIb-4) or (IIb-5)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, R1, R4, R5, R6and R7are as defined above.
[0106] According to a preferred embodiment, the structural analog of the invention is compounds formula (III)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, Y, R1, R4, R5, R6, A and B are as defined in formula (I).
[0107] According to a preferred embodiment, compound of formula (III) is of formulae (Illa) or (Illb)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, Y, A, B, R1, R4, R5and R6are as defined above.
[0108] In a preferred embodiment, the structural analog of the invention is of formula (Illa).
[0109] According to a preferred embodiment, compound of formula (Illa) is of formulae (IIIa-1) or (IIIa-2)(IIIa-1) or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, A, B, R1, R4, R5and R6are as defined above.
[0110] In a preferred embodiment, the structural analog of the invention is of formula (IIIa-1). In another preferred embodiment, the structural analog of the invention is of formula (IIIa-2).
[0111] According to a preferred embodiment, compound of formula (IIIa-1) is of formulae (IIIa-1’), (Illa- 1 ”) or (IIIa-1’”)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein A, B, R1, R4, R5and R6are as defined above.
[0112] In a preferred embodiment, the structural analog of the invention is of formula (IIIa-1’) or (IIIa-1”), more preferably of formula (IIIa-1’).
[0113] According to a preferred embodiment, compound of formula (IIIa-2) is of formulae (IIIa-2’), (IIIa-2”) or (IIIa-2’”)(IIIa-2’”)(IIIa-2’) (IIIa-2”)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein A, B, R1, R4, R5and R6are as defined above.
[0114] In a preferred embodiment, the structural analog of the invention is of formula (IIIa-2’) or (IIIa-2”).
[0115] According to a preferred embodiment, compound of formula (Illa- 1 ) and (IIIa-2) is of formulae (Illa-la), (Illa-lb), (Illa-lc), (Illa-ld), (Illa-le), (IIIa-2a), (Illa- 2b), (Illa- 2c), (IIIa-2d) or (IIIa-2e)(Illa- la) (Illa-lc)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, R1, R4, R5, R6and R7are as defined above.
[0116] In a preferred embodiment, the structural analog of the invention is of formula (Illa-la), (Illa-lb), (Illa-le), (IIIa-2a), (IIIa-2b) or (IIIa-2e), more preferably of formula (Illa- lb).
[0117] According to a preferred embodiment, compound of formula (Illb) is of formulae (Illb’), (Illb”) and (Illb’”)(Illb )or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein A, B, R1, R4, R5and R6are as defined above.
[0118] According to a preferred embodiment, compound of formula (Illb) is of formulae (IIIb-1), (IIIb-2), (IIIb-3), (IIIb-4) or (IIIb-5)R4(IIIb-1)or a pharmaceutically acceptable tautomer, salt or solvate thereof, wherein X, R1, R4, R5, R6and R7are as defined above.
[0119] According to a specific embodiment, the structural analog of the invention is selected from:5-(4-hydroxyphenyl)-377-l,2-dithiole-3-thione (AOX);5-(4-hydroxyphenyl)-377-l,2-dithiol-3-one (Cpl);5-(4-hydroxyphenyl)-377-l,2-dithiol-3-one oxime (Cp2);5-(4-hydroxyphenyl)-377-l,2,4-dithiazole-3-thione (Cp3);4-(4-hydroxyphenyl)-377- 1 ,2-dithiole-3-thione (Cp4);5-(2-hydroxybenzo[t / ]oxazol-5-yl)-377-l,2-dithiole-3-thione (Cp5);5-(2-hydroxybenzo[t / ]thiazol-6-yl)-377-l,2-dithiole-3-thione (Cp6a);5-(benzofuran-5-yl)-377-l,2-dithiole-3-thione (Cp8); andmethyl 5-(3-thioxo-377-l,2-dithiol-5-yl)-177-indole-l-carboxylate (Cp9a).
[0120] According to a preferred embodiment, the structural analog of the invention is selected from AOX, Cpl, Cp3, Cp4, Cp5, Cp6a and Cp9a. According to a preferred embodiment, the structural analog of the invention is selected from AOX, Cpl, Cp3, Cp5 and Cp6a.
[0121] According to a preferred embodiment, the structural analog of the invention is AOX
[0122] This invention also relates to a pharmaceutical composition for use in preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof, comprising Anethole trithione (AOL) or a structural analog thereof as described herein and at least one pharmaceutically acceptable excipient.
[0123] In some embodiments, the excipient is selected from a list consisting of cosolvents, buffers, saline, Ringer’s solution, dextrose solution, and solutions of ethanol, glucose, sucrose, dextran, mannose, mannitol, sorbitol, gelatin, collagen, Carbopol®, vegetable oils, and the like. The composition may additionally include suitable preservatives, stabilizers, antioxidants, antimicrobials, and buffering agents, such as, e.g., BHA, BHT, citric acid, ascorbic acid, tetracycline, and the like. In some embodiments, the composition further comprises at least one osmotic pressure regulating excipient such as for example sucrose or mannitol.
[0124] In some embodiments, the composition comprises a buffer selected from citrate buffer, tris(hydroxymethyl)aminomethane (Tris) buffer, 4- (2-hydroxy ethyl) -1 -piperazine ethanesulfonic acid (HEPES) buffer, ammonium sulfate, carbonate or acetate buffer.
[0125] In some embodiments, the composition comprises a buffer selected from citrate buffer, acetate buffer, tris or phosphate buffer. In some embodiments, the composition comprises a buffer selected from Tris or phosphate buffer.
[0126] In some embodiments, the composition comprises a buffer, preferably a phosphate buffer in an amount ranging from 10 to 150 mM, from 10 to 140 mM, from 25 to 140 mM, from 15 to 35 mM or from 60 to 140 mM.
[0127] In some embodiments, the aqueous composition does not comprise a buffer.
[0128] In some embodiments, the aqueous composition does not comprise a phosphate buffer.
[0129] In some embodiments, the pH of the aqueous solution ranges from 5 to 8, from 5.5 to 7.8, from 6 to 7.8 or from 6.5 to 7.5. In some embodiments, the pH of the aqueous solution is about 5.0, about 5.5, about 5.8, about 6.0, about 6.2, about 6.5, about 6.8, about 7.0, about 7.2, about 7.4, about 7.5, about 7.6, or about 7.8.
[0130] Other examples of pharmaceutically acceptable excipients that may be used in the composition of the invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, sodium carboxymethylcellulose, poly acrylates, waxes, polyethylene-polyoxypropylene- block polymers, polyethylene glycol and wool fat.
[0131] In addition some excipients may include, surfactants (e.g., hydroxypropylcellulose); suitable carriers, such as, e.g., solvents and dispersion media containing, e.g., water, ethanol, polyol e.g., glycerol, propylene glycol, and liquidpolyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils, such as, e.g., peanut oil and sesame oil; isotonic agents, such as, e.g., sugars or sodium chloride; coating agents, such as, e.g., lecithin; agents delaying absorption, such as, e.g., aluminum monostearate and gelatin; preservatives, such as, e.g., benzalkonium chloride, benzethonium chloride, chlorobutanol, thimerosal and the like; buffers, such as, e.g., boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, sodium biphosphate and the like; tonicity agents, such as, e.g., dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, sodium chloride; antioxidants and stabilizers, such as, e.g., sodium bisulfite, sodium metabisulfite, sodium thiosulfite, thiourea and the like; nonionic wetting or clarifying agents, such as, e.g., polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol; viscosity modifying agents, such as, e.g., dextran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose, hydroxymethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose; and the like.
[0132] In view of obtaining concentrated compound of formula (I) within aqueous and not highly- viscous compositions, the composition of the invention may further comprise at least one excipient.
[0133] In some embodiments, the at least one pharmaceutically acceptable excipient is a co-solvent.
[0134] In some embodiments, at least one co-solvent is selected from a group consisting of polysorbates, propylene glycol, glycerin, paraffin oil, alpha-tocopherol, dimethyl sulfoxide, N-methyl-2-pyrrolidone, glycofurol, Solketal, glycerol formal, acetone, ethanol, tetrahydrofurfuryl alcohol, diglyme, dimethylacetamide, dimethyl isosorbide, ethyl lactate, Cremophor EL, Cremophor RH 40, Cremophor RH 60, Solutol HS 15, poloxamer 407, Labrasol, Gellucire 44 / 14, Softigen 767, mono- and di-fatty acid esters mono- and di-fatty acid esters of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1750, PEG 2000 to 20000, PEG 1000 succinate; hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, L-a-dimyristoylphosphatidylcholine and L-a-dimyristoyl-pho sphatidylglycerol .
[0135] In some embodiments, at least one co-solvent is selected from a group consisting of polysorbates, propylene glycol, glycerin, paraffin oil, alpha-tocopherol, dimethyl sulfoxide, N-methyl-2-pyrrolidone, glycofurol, Solketal, glycerol formal, acetone, ethanol, tetrahydrofurfuryl alcohol, diglyme, dimethylacetamide, dimethyl isosorbide, ethyl lactate, Cremophor RH 40, Cremophor RH 60, Solutol HS 15, poloxamer 407, Labrasol, Gellucire 44 / 14, Softigen 767, mono- and di-fatty acid esters mono- and difatty acid esters of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1750, PEG 2000 to 20000, PEG 1000 succinate; hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, L-a-dimyristoylphosphatidylcholine and L-a-dimyristoyl-pho sphatidylglycerol .
[0136] In some embodiments, at least one co-solvent is selected from a group consisting of polysorbates, propylene glycol, glycerin, paraffin oil, alpha-tocopherol, dimethyl sulfoxide, N-methyl-2-pyrrolidone, glycofurol, Solketal, glycerol formal, acetone, ethanol, tetrahydrofurfuryl alcohol, diglyme, dimethylacetamide, dimethyl isosorbide, ethyl lactate, Solutol HS 15, poloxamer 407, Labrasol, Gellucire 44 / 14, Softigen 767, mono- and di-fatty acid esters mono- and di-fatty acid esters of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1750, PEG 2000 to 20000, PEG 1000 succinate; hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, L-a-dimyristoylphosphatidyl-choline and L-a-dimyristoyl-phosphatidylglycerol.
[0137] In some embodiments, at least one co-solvent is selected from a group consisting of polysorbates, propylene glycol, glycerin, paraffin oil, alpha-tocopherol, dimethyl sulfoxide, N-methyl-2-pyrrolidone, glycofurol, Solketal, glycerol formal, acetone, ethanol, tetrahydrofurfuryl alcohol, diglyme, dimethylacetamide, dimethyl isosorbide, ethyl lactate, poloxamer 407, Labrasol, Gellucire 44 / 14, Softigen 767, mono- and di-fatty acid esters mono- and di-fatty acid esters of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1750, PEG 2000 to 20000, PEG 1000 succinate; hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, L-a-dimyristoylphosphatidylcholine and L-a-dimyristoyl-pho sphatidylglycerol .
[0138] In some embodiments, at least one co-solvent is selected from a group consisting of polysorbates, propylene glycol, glycerin, paraffin oil, alpha-tocopherol, N-methyl-2-pyrrolidone, glycofurol, Solketal, glycerol formal, acetone, ethanol, tetrahydrofurfuryl alcohol, diglyme, dimethylacetamide, dimethyl isosorbide, ethyl lactate, poloxamer 407, Labrasol, Gellucire 44 / 14, Softigen 767, mono- and di-fatty acid esters mono- and difatty acid esters of PEG 200, PEG 300, PEG 400, PEG 600, PEG 1750, PEG 2000 to 20000, PEG 1000 succinate; hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, L-a-dimyristoylphosphatidylcholine and L-a-dimyristoyl-pho sphatidylglycerol .
[0139] Polysorbates may be selected from polysorbate 80, polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 65. Preferably, the polysorbate is polysorbate 80, polysorbate 20 and mixtures thereof.
[0140] In some embodiments, the at least one co-solvent is selected from a group consisting of polysorbate 80, polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 65, propylene glycol, alpha-tocopherol, dimethyl sulfoxide, N-methyl-2-pyrrolidone, ethanol, tetrahydrofurfuryl alcohol, diglyme, dimethylacetamide, dimethyl isosorbide, polyethylene glycol 1000 succinate, poloxamer 407, mono- and di-fatty acid esters of PEG 300, 400, or 1750.
[0141] In some embodiments, the at least one co-solvent is selected from a group consisting of polysorbate 80, polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 65, propylene glycol, alpha-tocopherol, N-methyl-2-pyrrolidone, ethanol, tetrahydrofurfuryl alcohol, diglyme, dimethylacetamide, dimethyl isosorbide, polyethylene glycol 1000 succinate, poloxamer 407, mono- and di-fatty acid esters of PEG 300, 400, or 1750.
[0142] In some embodiments, the at least one co-solvent is selected from a group consisting of polysorbate 80, polysorbate 20 and mixtures thereof, propylene glycol, alpha-tocopherol, dimethyl sulfoxide, ethanol, tetrahydrofurfuryl alcohol, diglyme, polyethylene glycol (PEG) 1000 succinate, poloxamer 407, mono- and di-fatty acid esters of PEG 300, 400, or 1750.
[0143] In some embodiments, the at least one co-solvent is selected from a group consisting of polysorbate 80, polysorbate 20 and mixtures thereof, propylene glycol,alpha-tocopherol, ethanol, tetrahydrofurfuryl alcohol, diglyme, polyethylene glycol (PEG) 1000 succinate, poloxamer 407, mono- and di-fatty acid esters of PEG 300, 400, or 1750.
[0144] In some embodiments, the at least one co-solvent is selected from a group consisting of ethanol, polyethylene glycol (PEG) 1000 succinate, mono- and di-fatty acid esters of PEG 300, 400, or 1750.
[0145] In some embodiments, the at least one co-solvent is selected from a group consisting of ethanol, PEG 300, 400, or 1750. In some embodiments, the at least one cosolvent is selected from a group consisting of ethanol and PEG 400.
[0146] In one preferred embodiment, the at least one pharmaceutically acceptable excipient is a co- solvent selected from polysorbates.
[0147] In one preferred embodiment, the at least one pharmaceutically acceptable excipient is a co-solvent selected from polysorbates selected from a list consisting of polysorbate 80, polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 65 and mixtures thereof.
[0148] In one preferred embodiment, the at least one pharmaceutically acceptable excipient is polysorbate 80, polysorbate 20 or mixtures thereof.
[0149] In one preferred embodiment, the at least one pharmaceutically acceptable excipient is polysorbate 80.
[0150] Raising the amount of the co-solvent positively correlates with the aqueous solubility of the compound of the invention. Nevertheless, the Applicant found that excessive use of co-solvents raises the viscosity of the composition and may be deteriorating for the compound’s chemical stability.
[0151] In some embodiments, the composition according to the present invention does not comprise a co-solvent.
[0152] In some embodiments, the composition according to the present invention comprises a co- solvent.
[0153] In some embodiments, the amount of co-solvent ranges from 1 to 40 % (w / w), from 1 to 30 % (w / w), from 1 to 20 % (w / w), preferably 2 to 15% (w / w), even more preferably from 5 to 10 % (w / w), in weight relative to the total weight of the composition.
[0154] In some embodiments, the amount of co-solvent ranges from 1 to 20 % (w / w), preferably 2 to 15% (w / w), even more preferably from 5 to 10 % (w / w), in weight relative to the total weight of the composition.
[0155] This invention further relates to a kit of parts comprising AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; and at least one other therapeutic agent.
[0156] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition, as described herein, is to be administered as monotherapy. In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition, as described herein, is to be administered as sole therapeutic agent.
[0157] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered before, concomitantly with or after at least one other therapeutic agent. In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition, as described herein, is to be administered simultaneously, separately, or sequentially with at least one other therapeutic agent.
[0158] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered with at least one other therapeutic agent.
[0159] In some embodiments, the other therapeutic agent is to be administered with AOL, the structural analog thereof, or the pharmaceutical composition; as described herein.
[0160] In some embodiments, the at least one other therapeutic agent is selected from the group consisting of: N-acetylcysteine (NAC), oltipraz (OPZ), and Ethyol® (Amifostine).
[0161] This invention also relates to AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; and the at least one other therapeutic agent for use in preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof.
[0162] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered before the radiation exposure.
[0163] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered 24 h, 23 h, 22 h, 21 h, 20 h, 19 h, 18 h, 17 h, 16 h, 15 h, 14 h, 13 h, 12 h, 11 h, 10 h, 9 h, 8 h, 7 h, 6 h, 5 h, 4 h, 3 h, 2 h, 1 h, 30 min, 10 min, 5 min before the radiation exposure.
[0164] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered 48 hours (h), 47 h, 46 h, 45 h, 44 h, 43 h, 42 h, 41 h, 40 h, 39 h, 38 h, 37 h, 36 h, 35 h, 34 h, 33 h, 32 h, 31 h, 30 h, 29 h, 28 h, 27 h, 26 h, 25 h, 24 h, 23 h, 22 h, 21 h, 20 h, 19 h, 18 h, 17 h, 16 h, 15 h, 14 h, 13 h, 12 h, 11 h, 10 h, 9 h, 8 h, 7 h, 6 h, 5 h, 4 h, 3 h, 2 h, 1 h, 30 minutes (min), 10 min, or 5 min before the radiation exposure.
[0165] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered from about 5 min to about 48 h, from about 30 min to about 24 h, before the radiation exposure.
[0166] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered after the radiation exposure.
[0167] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered 24 h, 23 h, 22 h, 21 h, 20 h, 19 h, 18 h, 17 h, 16 h, 15 h, 14 h, 13 h, 12 h, 11 h, 10 h, 9 h, 8 h, 7 h, 6 h, 5 h, 4 h, 3 h, 2 h, 1 h, 30 min, 10 min or 5 min after the radiation exposure.
[0168] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered 48 h, 47 h, 46 h, 45 h, 44 h, 43 h, 42 h, 41 h, 40 h, 39 h, 38 h, 37 h, 36 h, 35 h, 34 h, 33 h, 32 h, 31 h, 30 h, 29 h, 28 h, 27 h, 26 h, 25 h, 24 h, 23 h, 22h, 21 h, 20 h, 19 h, 18 h, 17 h, 16 h, 15 h, 14 h, 13 h, 12 h, 11 h, 10 h, 9 h, 8 h, 7 h, 6 h, 5 h, 4 h, 3 h, 2 h, 1 h, 30 min, 10 min or 5 min after the radiation exposure.
[0169] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered from about 5 min to about 48 h, from about 30 min to about 24 h, after the radiation exposure.
[0170] In some embodiments, AOL or the structural analog thereof is formulated for administration to the subject in need thereof.
[0171] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered systemically or locally.
[0172] In some embodiments, the systemic injections include, but are not limited to, intravenous (iv), subcutaneous (sq), intradermal (id), intramuscular (im), intraarterial, intraparenteral, intranodal, intralymphatic, intraperitoneal (ip), intracranial, intracardiac, intralesional, intraprostatic, intravaginal, intrarectal, intrathecal, intranasal, intratumoral (it), intravesicular, and perfusion.
[0173] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered by injection, orally, topically, nasally, buccally, rectally, vaginaly, intratracheally, by endoscopy, transmucosally, or by percutaneous administration, and preferably by injection.
[0174] In some embodiments, the injection is a bolus injection.
[0175] In some embodiments, the injection is a continuous infusion.
[0176] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be orally administered. Examples of formulations adapted to oral administration include, but are not limited to, solid forms, liquid formsand gels. Examples of solid forms adapted to oral administration include, but are not limited to, pill, tablet, capsule, soft gelatine capsule, hard gelatine capsule, caplet, compressed tablet, cachet, wafer, sugar-coated pill, sugar coated tablet, or dispersing / or disintegrating tablet, powder, solid forms suitable for solution in, or suspension in, liquid prior to oral administration and effervescent tablet. Examples of liquid form adapted to oral administration include, but are not limited to, solutions, suspensions, drinkable solutions, elixirs, sealed phial, potion, drench, syrup and liquor.
[0177] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is topically administered. Examples of formulations adapted to topical administration include, but are not limited to creams, gels, leave-on washes and / or the like.
[0178] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be transdermally administered, such as transdermal patch, more particularly as a sustained-release transdermal patch. The transdermal patches can include any conventional form such as, e.g., adhesive matrix, polymeric matrix, reservoir patch, matrix or monolithic-type laminated structure, and are generally comprised of one or more backing layers, adhesives, penetration enhancers, an optional rate controlling membrane and a release liner which is removed to expose the adhesives prior to application. Polymeric matrix patches also comprise a polymeric-matrix forming material. Suitable transdermal patches are described in more detail in, e.g., US Patents No. 5,262,165, 5,948,433, 6,010,715 and 6,071,531, the disclosure of each of which are incorporated herein in their entirety.
[0179] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; may be used in conjunction with delivery systems that facilitate delivery of the agents to the central nervous system. For example, various blood brain barrier (BBB) permeability enhancers may be used to transiently and reversibly increase the permeability of the blood brain barrier to a treatment agent. Such BBB permeability enhancers include but are not limited to leukotrienes, bradykinin agonists, histamine, tight junction disruptors (e.g., zonulin, zot), hyperosmotic solutions e.g., mannitol), cytoskeletal contracting agents, and short chain alkylglycerols (e.g., 1-O-pentylglycerol). Oral, sublingual, parenteral, implantation, nasal and inhalational routes can provide delivery of the active agent to the central nervous system. In some embodiments, the compounds of the present invention may be administered to the central nervous system with minimal effects on the peripheral nervous system.
[0180] The blood-brain barrier (BBB) is a physical barrier and system of cellular transport mechanisms between the blood vessels in the central nervous system (CNS) and most areas of the CNS itself. The BBB maintains homeostasis by restricting the entry of potentially harmful chemicals from the blood, and by allowing the entry of essential nutrients. However, the BBB can pose a formidable barrier to delivery of pharmacological agents to the CNS for treatment of disorders or maintaining or enhancing normal and desirable brain functions, such as cognition, learning, and memory.
[0181] In some embodiments, AOL, the structural analog thereof, or the pharmaceutical composition; as described herein; is to be administered in a part of the body of the subject thereof.
[0182] In some embodiments, the acute radiation syndrome is selected from the group consisting of: bone marrow, gastrointestinal, and neurovascular syndrome.
[0183] In some embodiments, the acute radiation syndrome is selected from the group consisting of: bone marrow syndrome, gastrointestinal syndrome, neurovascular syndrome, more preferably the bone marrow syndrome.
[0184] In some embodiments, the acute radiation syndrome is selected from the group consisting of: bone marrow syndrome, gastrointestinal syndrome and neurovascular syndrome, preferably bone marrow syndrome and gastrointestinal syndrome.
[0185] In some embodiments, the acute radiation syndrome is bone marrow syndrome.
[0186] In some embodiments, the acute radiation syndrome is gastrointestinal syndrome.
[0187] In some embodiments, the anethole trithione (AOL), or a structural analog thereof, for use in preventing, treating, and / or lessening acute radiation syndrome byrestoring the colon function, wherein the acute radiation syndrome is gastrointestinal syndrome.
[0188] In some embodiments, the acute radiation syndrome is selected from (a) hematopoietic acute radiation syndrome, (b) gastrointestinal acute radiation syndrome, (c) cutaneous acute radiation syndrome, (d) central nervous system (CNS) acute radiation syndrome, (e) hematopoietic, gastrointestinal, cutaneous or neurovascular subsyndrome of acute radiation syndrome, (f) cardiovascular (CV) acute radiation syndrome, or (g) pulmonary dysfunction acute radiation syndrome.
[0189] In some embodiments, anethole trithione (AOL) or a structural analog thereof as described herein has antioxidant effect, preferably antioxidant effect in bone marrow; even more preferably antioxidant effect in bone marrow immature hematopoietic stem cells (LT-HSC).
[0190] In some embodiments, anethole trithione (AOL) or a structural analog thereof as described herein has anti- apop to tic effect, more preferably anti-apoptotic effect in bone marrow; even more preferably anti-apoptotic effect in bone marrow immature hematopoietic stem cells (LT-HSC).
[0191] The invention further related to anethole trithione (AOL), or a structural analog thereof, for use in preventing, treating, and / or lessening diarrhea in a subject in need thereof diagnosed with acute radiation syndrome, preferably gastrointestinal syndrome, preferably by restoring the colon function.
[0192] This invention also relates to the use of anethole trithione (AOL) or a structural analog thereof; as described herein; for preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof.
[0193] This invention further relates to a method of preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of anethole trithione (AOL) or a structural analog thereof; as described herein.
[0194] Additionally, this invention relates to the use of anethole trithione (AOL) or a structural analog thereof; as described herein; for the manufacture of a medicament for the prevention, the treatment, and / or the lessening of acute radiation syndrome in a subject in need thereof.
[0195] This invention also relates to the pharmaceutical composition for use for the prevention, the treatment, and / or the lessening of acute radiation syndrome in a subject in need thereof comprising an anethole trithione (AOL) or a structural analog thereof; as described herein.
[0196] This invention also relates to anethole trithione (AOL) or a structural analog thereof; as described herein; for use as a medicament for the prevention, the treatment, and / or the lessening of acute radiation syndrome in a subject in need thereof.
[0197] This invention further relates to use of agent anethole trithione (AOL) or a structural analog thereof; as described herein; for the prevention, the treatment, and / or the lessening of acute radiation syndrome in a subject in need thereof.
[0198] Moreover; the invention also relates to the product anethole trithione (AOL) or a structural analog thereof; as described herein; for use in the preparation of a medicament for the prevention, the treatment, and / or the lessening of acute radiation syndrome in a subject in need thereof.BRIEF DESCRIPTION OF THE DRAWINGS
[0199] Figure 1 is a Schematic illustration of the RIANS model. The numbers indicate the different steps (1: irradiation; 2: monomerization of the ATM dimers; 3: diffusion of the ATM monomers in the nucleus; 4: recognition of the DSB sites by the phosphorylation of the surrounding H2AX histones)
[0200] Figure 2 is a Representative illustration of DSB repair kinetics from yH2AX or pATM foci data. The dashed line indicates the full DSB recognition and repair steps while the solid line indicates impaired DSB recognition and repair steps
[0201] Figure 3 is a graph showing a number of yH2AX foci assessed by immunofluorescence after a 24 h pre-treatment AOL in DMSO 0.1% at the indicated concentration at 10 min (A) or 24 h (B) post-irradiation. Data were obtained from the indicated cell lines. The grey area of panel A reflects full DSB recognition while the grey of panel B area reflects the normal DSB repair step. Each plot represents the mean ± standard error of the mean of at least, 3 independent replicates.
[0202] Figure 4 is a graph showing a number of yH2AX foci assessed after 2 to 10 Gy X-rays on the radioresistant 1BR3 fibroblasts after an AOL pre-treatment of 10 pM AOL for 24 h (radioprotection) (panels A and B) or a post- treatment of 10 p M AOL for 1 h (radiomitigation) (panel C). Each plot represents the mean ± standard error of the mean of at least, 3 independent replicates. The open symbols and the dashed lines represent the data obtained after the pre-treatment (panels A and B) or the post-treatment of AOL drug.
[0203] Figure 5 is a graph showing a number of yH2AX foci assessed after 2 to 10 Gy X-rays on the radioresistant 1BR3 fibroblasts (reproduction of Fig. 4A) with data obtained from an OLTIPRAZ pre-treatment of 10 pM for 24 h (radioprotection) (small open squares). Each plot represents the mean ± standard error of the mean of at least, 3 independent replicates. Error bars were omitted for clarity.
[0204] Figure 6 is a graph showing a number of spontaneous yH2AX foci assessed in two radioresistant 1BR3 and Hs27 fibroblasts and two radiosensitive (group II) after a pre-treatment with the indicated drug for 24 h. Each plot represents the mean ± standard error of the mean of at least, 3 independent replicates. The asterisks represent the statistical differences with the controls (1,2, 3, 4 asterisks mean p<0.05, p<0.01, p<0.001, p<0.0001, respectively). The concentrations of drugs for each pre-treatment were: zoledronate: 1 uM; pravastatine : 1 uM; ZOPRA = 1 uM zoledronate + 1 uM pravastatine; NAC : 96mM; amifostine : 300 mM; AOL : 10 uM; Oltipraz : 30 uM.
[0205] Figure 7 is a graph showing a number of yH2AX foci assessed after 2 Gy + 10 min post-treatment in two radioresistant 1BR3 and Hs27 fibroblasts and two radiosensitive (group II) after a pre-treatment with the indicated drug for 24 h. Each plot represents the mean ± standard error of the mean of at least, 3 independent replicates. Theasterisks represent the statistical differences with the controls (1,2, 3, 4 asterisks mean p<0.05, p<0.01, p<0.001, p<0.0001, respectively). The concentrations of drugs for each pre-treatment were: zoledronate: 1 uM; pravastatine : 1 uM; ZOPRA = 1 uM zoledronate + 1 uM pravastatine; NAC : 96mM; amifostine : 300 mM; AOL : 10 uM; Oltipraz : 30 uM.
[0206] Figure 8 is a graph showing a number of yH2AX foci assessed after 2 Gy + 24 h post-treatment in two radioresistant 1BR3 and Hs27 fibroblasts and two radiosensitive (group II) after a pre-treatment with the indicated drug for 24 h. Each plot represents the mean ± standard error of the mean of at least, 3 independent replicates. The asterisks represent the statistical differences with the controls (1,2, 3, 4 asterisks mean p<0.05, p<0.01, p<0.001, p<0.0001, respectively). The concentrations of drugs for each pretreatment were: zoledronate: 1 uM; pravastatine: 1 uM; ZOPRA = 1 uM zoledronate + 1 uM pravastatine; NAC: 96mM; amifostine: 300 mM; AOL: 10 uM; Oltipraz: 30 uM.
[0207] Figure 9 is a graph showing a survival histogram of adult male mice, total body irradiated with 8.1 Gy and treated with AOL (n=10 mice) or its vehicle (n=10 mice) in comparison with non-irradiated mice treated with AOL (n=3 mice) or its vehicle (n=3 mice). The data of the comparison is not shown, but no significant difference was observed between these irradiated groups. Remaining mice were euthanized 16 days post-TBI (Total Body Irradiation) to collect tissues for histology or flow cytometry analysis.
[0208] Figure 10 is a graph showing the percentage of bone marrow LT-HSC with intracellular ROS measured by flow cytometry in mice 24h after a 8.1 Gy-TBI followed by a treatment with AOL (n=6 mice) or its vehicle (n=6 mice) in comparison with nonirradiated mice treated with AOL (n=2 mice) or its vehicle (n=2 mice).
[0209] Figure 11 is a graph showing the percentage of apoptotic bone marrow LT-HSC measured by flow cytometry in mice 24h after an 8.1 Gy-TBI followed by a treatment with AOL (n=6 mice) or its vehicle (n=6 mice) in comparison with non-irradiated mice treated with AOL (n=2 mice) or its vehicle (n=2 mice).Figure 12 is a graph showing the Tunel area / Mask area which were measured in Crypts (A) and Vills (B) from intestinal incisions in mice 24h after a 8.1 Gy-TBI followed bytreatment with AOL (n=10 mice) or its vehicle (n=10 mice) in comparison with nonirradiated mice treated with AOL (n=3 mice) or its vehicle (n=3 mice).EXAMPLES
[0210] The present invention is further illustrated by the following examples.The RIANS model
[0211] The radioprotective action of the AOL drug has been documented in a context of the mechanistic model of the individual response to ionizing radiation based on the nucleo shuttling of the ATM protein and developed by the U1296 Inserm unit entitled « Radiation: Defense, Health, and Environment » (Berthel et al., Cancers, 2019). This mechanistic model notably permits to distinguish the DNA damage recognition steps from the DNA damage repair step, two notions that are essential in the understanding of the action of the AOL drug (Berthel et al., Cancers, 2019; and Restier-Verlet et al., Biomolecules, 2023). The radiation-induced ATM nucleo shuttling (RIANS) model is based on the following steps: 1) ionizing irradiation produces oxidative stress resulting from the radiolysis of water which induces DNA breaks in the nucleus and monomerization of the dimeric forms of the ATM protein, especially in the cytoplasm where they are abundant; 2) ATM monomers diffuse into the nucleus in which they ensure the recognition of DNA double-strand breaks (DSB), key damage in the response to radiation. The DSB recognition step is revealed by the phosphorylation of histone H2AX variants (yH2AX) surrounding the DSBs site by the ATM monomers. Such step produces the formation of nuclear yH2AX foci at each individual DSB site. The yH2AX foci are easily quantifiable by immunofluorescence and permit to establish the DSB repair kinetics, when their number is plotted as a function of the post- irradiation repair time [3]. Once the DSB sites are, recognized, the DSB repair proteins are recruited and the DSB repair can be processed. Once repair takes place, two ATM monomers come together and redimerize by autophosphorylating (pATM) at the DSB sites by forming pATM foci, also easily quantifiable by immunofluorescence (Berthel E. et al., Cancers, 2019; Restier-Verlet J. et al., Biomolecules, 2023; Rothkamm K. et al, Proceedings of the NationalAcademy of Sciences of the United States of America, 2003; and Maalouf M. et al., international journal of radiation oncology, biology, physics, 2019). Plotting the number of pATM foci as a function of post-irradiation time is another way to consider DSB repair kinetics; 3) Any delay (or absence) of the ATM nucleo shuttling leads to a certain radiosensitivity which may be accompanied by a high risk of radiation-induced cancer (radiosusceptibility) or accelerated aging (radiodegeneration) (Foray N. et al., Mutation Research Review, 2016) (Fig. 1).of the DSB ir kinetics from immunofluorescence foci data
[0212] In humans, the DSB recognition is completed at the first 10 min post-irradiation and 50% of the DSB repair is done in the first hour followed by 2 Gy X-rays (Foray N. et al., Mutation Research Review, 2016). At 24-72 h post-irradiation, it is generally considered that DSB repair is completed and the unrepaired DSB are fixed (Foray N. et al., Mutation Research Review, 2016). Hence, the number of yH2AX and pATM foci assessed in the first hour post-irradiation reflects the DSB recognition while the 24-72 h data reflect the DSB repair. For example, in a DSB repair kinetics curve, the increase of the number of yH2AX and pATM foci assessed in the first hour post-irradiation is interpreted as an increase of the DSB recognition instead of an increase of the induction of new DNA breaks (Fig. 2). Similarly, the decrease of the number of yH2AX and pATM foci assessed at 24 h post-irradiation reflects a better DSB repair (Fig.2).1: Data obtained at 2 Gv. Validation of the RIANS modelMaterials and MethodsCell lines
[0213] Untransformed fibroblast cell lines were chosen for their genomic stability and to avoid any confounding effect of immortalization. Cells were routinely cultured as monolayers with Dulbecco’s modified Eagle’s minimum medium (DMEM) (Gibco-Invitrogen-France, Cergy-Pontoise, France), supplemented with 20% fetal calf serum, penicillin and streptomycin. Cells were routinely maintained at 37°C in a humid atmosphere at 5% CO2 in 150 cm2 flasks for less than 5 days. For all the assays described below, confluent cultures were softly detached with 0.025% trypsin and 0.02% ethylenediaminetetraacetic acid (EDTA) (Gibco-Invitrogen-France, Cergy-Pontoise, France) to obtain single cell suspensions that are reseeded for routine culture at dilution 1:2 to 1:4 according to the doubling times. Only cells at passages lower than 15 were used for all the experiments. For all the experiments, the cells were seeded 3 days before the experiment in 6-cm plastic Petri dishes (containing glass slides for immunofluorescence only). All the experiments were performed with cells in plateau phase of growth (95 - 99 % in G0 / G1) to overcome any cell cycle effects. The distribution of cells in the different cell cycle phases is routinely controlled by using flow cytometry. All the transport of cells (notably to the irradiators) was perfomed in a dedicated safety cooled box.X-rays irradiation
[0214] Irradiations were performed with a 6 MeV X-rays medical irradiator (SL 15 Philips) (dose-rate: 6 Gy.min-1) at the anti-cancer Centre Leon-Berard (Lyon, France). In all the experiments, a dose of 2 Gy was chosen because it simulates a current dose per session in a standard radiotherapy.Immunofluorescence
[0215] Cells were fixed in paraformaldehyde for 10 min at room temperature and were permeabilized in 0.5% Triton X-100 solution for 5 min at 4°C. Anti-yH2AXserl39 antibody (#05-636; Merck Millipore, Burlington, USA) was used at 1:800. Incubations with anti-mouse fluorescein (FITC) and rhodamine (TRITC) secondary antibodies were performed at 1:100 at 37°C for 20 min. Slides were mounted in 4',6'Diamidino-2-Phenyl-indole (D API)- stained Vectashield (Cliniscience, Nanterre, France) and examined with Olympus BX51 fluorescence microscope. DAPI staining permitted also to indirectlyevaluate yield of G1 cells (nuclei with homogeneous DAPI staining), S cells (nuclei showing numerous yH2AX foci), G2 cells (nuclei with heterogeneous DAPI staining) and metaphase (visible chromosomes).
[0216] Foci scoring procedure applied here has received the certification agreement of CE mark and ISO- 13485 quality management system norms but developed some features protected in the frame of the Soleau Envelop and patents (FR3017625 Al, FR3045071 Al, EP3108252 Al).Results
[0217] After a 24 h pre-treatment of AOL whose concentration is indicated in the Figure 3, the radioresistant Hs27 and 1BR3 fibroblast and the radiosensitive (group II) 14CLB and GM01142 fibroblast cell lines were irradiated at 2 Gy X-rays: the DSB repair kinetics were obtained from anti-yH2AX immunofluorescence technique (Fig. 3).
[0218] As said above, the 10 min data reflect the DSB recognition by ATM. The Figure 3A shows that the number of yH2AX foci 10 min post-irradiation data provided by radioresistant control cells decreased progressively while the concentration of AOL increased, likely due to the anti-oxidative property of the AOL molecule (p<0.05). By contrast, data from the radiosensitive cells which suffer from a lack of complete DSB recognition (i.e. a delayed RIANS) showed a significant increase of the number of yH2AX assessed 10 min post-irradiation, strongly suggesting that the AOL drug facilitates the RIANS to proceed and, consequently, increases the DSB recognition, as hypothesized above (Eig. 3A). In these conditions, the maximal effect with AOL pretreatment was observed at 30 uM by increasing DSB recognition of 45% at least (from 30 to 55 yH2AX foci) (Eig. 3A).
[0219] As said above, the 24 h data reflect the DSB repair. The Eigure 3B shows that the number of yH2AX foci 24 h post-irradiation data provided by radioresistant control cells are already very low (p>0.5). By contrast, with the radiosensitive cells, the number of yH2AX assessed 24 h post-irradiation decreased significantly while AOL concentrationincreased, and reached the zone of non-toxicity (less than 2 yH2AX foci per cell). These data suggest that the AOL drug facilitates the RIANS, increases the DSB recognition, which has a significant impact on DSB repair (Fig. 3B).Hypotheses from the RIANS model for doses higher than 2 Gy
[0220] In the frame of RIANS model, the number of ATM monomers produced is proportional to the dose of radiation (Berthel E. el al., Cancers, 2019). In the context of high doses of radiation (i.e. higher than 2 Gy, preferably 4 Gy), the number of radioinduced ATM monomers provided from the ATM dimers is such that the monomers redimerize in the cytoplasm before reaching the nucleus because of high concentrations favoring interactions. Thus, from a threshold dose, ATM can no longer recognize DSB: the number of yH2AX foci should decrease drastically.Example 2: Data obtained at doses higher than 2 Gy. Validation of the RIANS modelMaterials and Methods
[0221] The same Materials and Methods apply here than the one described above for Example 1.Results
[0222] By exposing one radioresistant skin fibroblast cell line (1BR3) to high doses of radiation, we observed a reduction in the number of yH2AX foci at more than 2Gy and from 4 Gy at early times post-irradiation (Fig. 4A). From 6 Gy, at lOmin and 1 h repair time, the decrease of the number of yH2AX foci reached a second step as if the redimerization of the ATM monomers was biphasic (in a possible belt of ATM dimers may be progressively formed around the nucleus, which may delay again the RIANS).
[0223] The AOL pre-treatment (10 uM for 24 h before irradiation; red plots ad lines) was applied to the radioresistant skin fibroblast cell line (1BR3). The AOL pre-treatmentmade it possible to significantly increase the number of yH2AX foci from early times (10 min and 1 h) by increasing the number of recognized DSB. Particularly, the AOL pretreatment permitted to reach 100% of the expected value of yH2AX foci at 4 Gy+10 min and 50% of the expected value of yH2AX foci at 8 Gy + 10 min (Fig. 4A). Similarly, the AOL pre-treatment permitted to reach 100% of the expected value of yH2AX foci at 4 Gy + Ih and 50% of the expected value of yH2AX foci at 8 Gy + Ih. because of a better DSB recognition at early times (Fig. 4A).
[0224] The number of DSB remaining at long times (24 to 72 h) post-irradiation decreased after the AOL pre-treatment for all the doses tested (Fig. 4B). Particularly, the AOL pre-treatment decreased significantly the number of yH2AX foci assessed at 8 Gy and 10 Gy at 24 h (from 10 to 0; p<0.001) (Fig. 4B).
[0225] The AOL post-treatment applied 4 h after irradiation with 10 uM AOL has an impact. It must be noteworthy that, 1 h after irradiation, 50% of the cells are already repaired showing the benefit of AOL post-treatment (Fig 4C).
[0226] So, AOL, whether a pre- or a post-treatment shows a significant change in the number of yH2AX foci for any time and dose investigated, and so showing the DSB repair after irradiation.
[0227] Finally, it must be stressed that, whether a pre- or a post-treatment were applied with the Oltipraz molecule, no significant change was observed in the number of yH2AX foci for any time and dose investigated (Fig. 5).
[0228] The AOL drug pre-treatment permits a better DSB recognition from 2 to 8 Gy early post-irradiation and, consequently, may facilitate DSB repair at later post- irradiation times like 24 h to 72h.
[0229] As said previously, the antioxidative drugs act at the chemical level during the water lysis and the formation of reactive oxygen species, whether the process is spontaneous (leading to spontaneous DSB) or induced by a given genotoxic stress (e.g. leading to radiation-induced DSB). The antioxidative approach leads to the decrease of the final product of water lysis, namely oxygen peroxide, therefore leading to the decreaseof the number of DSB induced.
[0230] By contrast, the proepiskevic drugs act at the molecular level by facilitating the diffusion of the ATM monomers produced by the genotoxic stress in the nucleus. One of the earliest consequences of this nucleo-shuttling of the ATM protein is a better recognition of DSB through the phosphorylation of the H2AX molecules surrounding the DSB sites. Such DSB recognition is the first step of the DSB repair. Hence the proepiskevic action is first associated to an increase of the number of yH2AX foci as far as this number has not reached the total number of DSB induced.
[0231] Interpretation of the spontaneous DSB data. The general trend is a significant decrease of the number of spontaneous DSB of the radiosensitive cells (the corresponding level of the radioresistant controls decreases as well but it is so low that there is no statistical significance). With antioxy dative drugs treatment, the decrease of the permanent ROS production leads to a lower number of DSB. With the proepiskevic drugs treatment, there are more DSB recognized therefore more DSB repaired. AOL seems to combine both properties even if the differences between the other drugs are not significant (Fig- 6).
[0232] Interpretation of the recognized DSB data. After 2 Gy X-rays, we expect 40 x 2 = 80 DSB induced and recognized, therefore 80 yH2AX foci at 10 min post-irradiation. Hence, in radioresistant controls, the pro-episkevic drugs do not change the picture since all the DSB are recognized. Conversely, for anti-oxydative drugs, the number of yH2AX should be lower (not significant but for AOL). For radiosensitive cells, the fraction of non-recognized DSB is about 15 for 14CLB and 50 for 15 CLB. With anti-oxydative drugs, the number of DSB induced should decrease the number of DSB and therefore the number of foci: it is observed for the 14CLB cell line but no for the 15CLB cell line. By increasing the number of DSB recognized, the pro-episkevic drugs increase the number of foci accordingly. Such effect is maximal for AOL (Fig. 7)
[0233] Interpretation of the repaired DSB data. The level of the yH2AX foci in radioresistant controls is so low than no action is significant. For radiosensitive cell lines, since more DSB have been recognized at 10 min after proepiskevic drugs treatment, moreDSB are repaired. Conversely, the decrease of the number of DSB induced due to the antioxydative drugs does not enhance the DSB repair process and therefore there is no significant decrease of DSB repaired with NAC, amifostine or oltipraz. Again, the pro-eipskevic action of AOL seems to be higher than the ZOPRA treatment (Fig. 8).Example 3: Data obtained using murine modelsMaterials and Methods
[0234] Mice
[0235] Ten to 12-week-old C57BL / 6 male mice were purchased from Janvier-Labs (C57BL / 6JRj - Le Genest Saint Isle, France). Experimental procedures were performed in accordance with the European Community Council Directive (EC / 2010 / 63) and were approved by our ethic committee (APAFIS #44906-2023092215246249 v2). All mice were housed in our specific-pathogen-free-animal facility (EU Agreement number D92-032-02) and handled in compliance with the institutional guidelines and French Ministry of Agriculture’s regulations. Every effort was made to minimize suffering by adding enrichment such as cotton and tunnels.
[0236] Total Body Irradiation (TB1)
[0237] Irradiations were performed on a GSR-D1 irradiator (Gamma-Service Medical GmbH company). It is a self-shielded irradiator with four 137Cesium sources for a total activity of 180.28 TBq which emits gamma rays. Mice were total body irradiated at 8.1 Gy with a dose rate of 0.95 Gy / min taking the radioactive decrease into account. Mice were irradiated in specific box designed solely for irradiation.
[0238] Treatments of mice: 4 groups
[0239] Survival and body weight study: N=1 experiment
[0240] Mice no-TBI + vehicle (n=3)
[0241] Mice no-TBI + AOL(n=3)
[0242] Mice TBI + vehicle (n=10)
[0243] Mice TBI + AOL (n=10)
[0244] Treatment was performed 30 min, 9 hours, 24 hours and 48 hours post- TBI through four gavages with a AOL dose of 10 mg / kg per gavage per mice, or with vehicle as control. Mice were weighted every 1 or 2 days in addition to a clinical score calculation. Mice were euthanized when the defined endpoint was reached.
[0245] All remaining mice were euthanized 16 days post-TBI. Tissues (femur, spleen, piece of small intestine, heart and lung) were collected for histological analysis.
[0246] Short-term bone marrow analysis: N=2 independent experiments
[0247] Mice no-TBI + vehicle (n=l+l)
[0248] Mice no-TBI + AOL(n=l+l)
[0249] Mice TBI + vehicle (n=3+3)
[0250] Mice TBI + AOL(n=3+3)
[0251] Treatment was performed 30 min and 9 hours post-TBI through two gavages with a AOL dose of 20 mg / kg per gavage per mice, or with vehicle as control.
[0252] Mice were then euthanized by cervical translocation 24 hours post-TBI.
[0253] Flow Cytometry
[0254] Flow cytometry analysis was performed with a BD FACSLSRII™ flow cytometer (BD Biosciences).
[0255] Bone marrow cells were flushed out of the humerus, femurs, tibias and pelvis using a syringe filled with PBS (DPBS). Red blood cells were lysed for 10 min with an ammonium chloride solution (STEMCELL™) and bone marrow cells were filtered through a 70pm-cell strainer.
[0256] Bone marrow cells were stained for 15 minutes at 4°C with different fluorescentantibodies.
[0257] Long-term Hematopoietic stem cells (LT-HSC) were defined as: Lineageneg, c-kit+, Sca-1+, CD135neg, CD48neg, CD150+.
[0258] Measurement of intracellular ROS and apoptosis
[0259] For intracellular ROS and apoptosis measurement in LT-HSC, previously stained bone marrow cells were suspended in DPBS (IX), calcium and magnesium supplemented with 5% Bovine Serum Albumin and incubated with the Molecular Probe™ CellROX™ Deep Red (5 pM final, 30 minutes at 37°C, Invitrogen #C10422). Cells were washed twice with DPBS w / o calcium and magnesium (Gibco) and the CellEvent™ Caspase-3 / 7 Green Detection Reagent (Invitrogen #C 10423) was added (1 / 1000 final) for 40 min at RT. Samples were then placed on ice until FACS analysis.
[0260] Statistical analysis
[0261] All statistical analysis was performed using Prism 10 (GraphPad Software). Two-tailed Mann-Whitney U test was used to evaluate the statistical significance between two groups. *P < 0.05 was considered statistically significant; **P < 0.01 was considered statistically very significant.Results
[0262] Survival analysis was performed on mice subjected to total body irradiation (8.1 Gy) and treated with either vehicle or AOL. The results showed a marked improvement in survival in the AOL-treated group compared to the vehicle control. Specifically, only 2 out of 10 mice survived in the vehicle group, whereas 4 out of 10 mice survived following AOL treatment, indicating a protective effect of AOL against radiation-induced lethality (Figure 9).
[0263] As shown in Figure 10, irradiation markedly increased the proportion of LT-HSCs with detectable intracellular ROS in vehicle-treated mice relative to non-irradiated controls. In contrast, treatment with AOL significantly reduced the percentage of ROS-positive LT-HSCs compared to irradiated vehicle-treated mice. Notably, ROS levels in LT-HSCs from AOL-treated mice approached those observed in non-irradiated groups.
[0264] These findings indicate that AOL effectively attenuates radiation-induced oxidative stress in LT-HSCs, supporting a role for this treatment in preserving redox homeostasis within the hematopoietic stem cell compartment following acute irradiation.
[0265] Moreover, as shown in Figure 11, irradiation induced a substantial increase in LT-HSC apoptosis in vehicle-treated mice relative to non-irradiated controls. In contrast, treatment with AOL significantly reduced the proportion of apoptotic LT-HSCs following irradiation. The levels of apoptosis observed in AOL-treated irradiated mice were markedly lower than those in irradiated vehicle-treated mice and thus closer to those measured in non-irradiated groups.
[0266] These results demonstrate that AOL attenuates radiation-induced apoptosis in LT-HSCs, showing a protective effect on stem cell survival in the bone marrow following acute irradiation, even short term after high dose TBI irradiation.
[0267] Thus, very short-term after a high dose TBI, AOL has a significant antioxidant and anti-apoptotic effect in bone marrow immature hematopoietic stem cells.Example 4: Data obtained for radiation-induced gastrointestinal syndrome
[0268] Radiation-induced gastrointestinal syndrome (GIS) often occurs after accidental exposure to high doses of radiation. At doses of more than 5 Gray, villous epithelial cells and crypt stem cells, which are essential for the regeneration of colon villi and constitute the epithelial integrity, were found to be apoptotic and even killed, causing epithelial damage.
[0269] Abundant evidence indicates that death of epithelial stem cells in the crypts leadsto gastrointestinal acute radiation syndrome.Materials and Methods
[0270] Mice
[0271] Ten to 12- week-old C57BL / 6 male mice were purchased from Janvier-Labs (C57BL / 6JRj - Le Genest Saint Isle, France). Experimental procedures were performed in accordance with the European Community Council Directive (EC / 2010 / 63) and were approved by our ethic committee (APAFIS #44906-2023092215246249 v2). All mice were housed in our specific-pathogen-free-animal facility (EU Agreement number D92-032-02) and handled in compliance with the institutional guidelines and French Ministry of Agriculture’s regulations. Every effort was made to minimize suffering by adding enrichment such as cotton and tunnels.
[0272] Total Body Irradiation (TBI)
[0273] Irradiations were performed on a GSR-D1 irradiator (Gamma-Service Medical GmbH company). It is a self-shielded irradiator with four 137Cesium sources for a total activity of 180.28 TBq (March 2014) which emits gamma rays. Mice were total body irradiated at 8.1 Gy with a dose rate of 0.95 Gy / min taking the radioactive decrease into account. Mice were irradiated in specific box designed solely for irradiation.
[0274] Treatments of mice: 4 groups
[0275] Survival and body weight study: N=1 experiment- Mice no-TBI + vehicle (n=3)- Mice no-TBI + AOL (n=3)- Mice TBI + vehicle (n=10)- Mice TBI + AOL (n=10)
[0276] Treatment was performed 30 min, 9 hours, 24 hours and 48 hours post-TBIthrough four gavages with a AOL dose of 10 mg / kg per gavage per mice, or with vehicle as control. Mice were euthanized 24 hours post-TBI. Tissues (femur, spleen, piece of small intestine, heart and lung) were collected for histological analysis.
[0277] Bowel apoptosis: Crypt and vill analysis with Tunel
[0278] The small intestine was resected and immersed in a 10% neutral-buffered formalin solution and embedded in paraffin for histopathological analysis under light microscopy, which was done by blinded pathologists. Four micrometers sections were then stained with hematoxylin and eosin (H & E). Identification of apoptosis was confirmed with a Terminal deoxynucleotidyl transferase-mediated nick end-labeling (TUNEL) technique that stains the oligofragmented DNA characteristically found in apoptotic nuclei using a commercial apoptosis detection kit (Roche Diagnostics GmbH, Penzberg, Germany). One hundred crypts per slide from the complete intestinal crypts that had been cut into transverse planes (6 pM) were scored for apoptosis. The incidence of cell death in the small intestine was quantified by counting the number of dead cells in each crypt with the H & E-stained sections at x 400 magnification by light microscopic analysis (LEICA SP8). The normal nuclei were stained using the Hoechst procedure. TUNEL / Hoechst staining is performed using the Click- iT™ Plus TUNEL Assay Kit (C10617 - Thermo Fischer). Through the extraction of the surface of color, the apoptosis counting was obtained by measuring the ratio of TUNEL surface and Mask area. The “Mask area” corresponds to the positive Hoechst surface within the relevant region (crypts or villi). This “Masking” applied during the analysis, makes it possible to distinguish between the villi and crypt regions, where the induction of apoptosis varies in degree.Results
[0279] The Figure 12 shows that 24hours post TBI, the level of apoptotic cells dramatically has increased in the crypts (Panel A) of intestine due to the severity of the radiation. In the vills (Panel B), the number of apoptotic cells has also increased but in less extent. The treatment with AOL post TBI markedly reduced the level of apoptoticcells both in the crypts and in the vills.
[0280] The present results clearly demonstrate that a curative treatment post TBI with AOL (10 mg / kg 3.a.d orally) can reduce the occurrence of apoptotic cells in the intestine crypts as well and in less extent in the vills. Taking into account that the leaking intestinal barrier in the crypt is certainly one of the life threatening concerns following ARS, AOL through its cytoprotective activity directly upon intestinal cells might be considerer as the first countermeasure able to directly restore the colon function and therefore, to prevent occurrence of diarrhea.
Claims
CLAIMS1. Anethole trithione (AOL), or a structural analog thereof, for use in preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof.
2. AOL, or the structural analog thereof, for use according to claim 1, wherein the subject has been exposed to ionizing radiation.
3. AOL, or the structural analog thereof, for use according to claim 2, wherein the subject has been exposed to ionizing radiation of more than 2 Gy.
4. AOL, or the structural analog thereof, for use according to any one of claims 1 to 3, wherein AOL or the structural analog thereof induces the diffusion of the ATM serine / threonine kinase (ATM protein) into the nucleus to stimulate DNA damage repair.
5. AOL, or the structural analog thereof, for use according to any one of claims 1 to 4, wherein the structural analog of AOL is a compound of formula (I):R2R1XRA Hl / >=\ ssR4R5(I)wherein:X represents S, O or NHOH; preferably X is S or O; more preferably, X is S;Y represents CH, C or N; preferably Y is CH or N; more preferably Y is CH;R1, R2, R4and R5each independently represent hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl;R3is methoxy or hydroxy; or R3and R2together with the carbon atoms to which they are attached form a 5-membered heteroaryl moiety wherein -R3-R2- represents -A-CR6=B- or -B=CR6-A-; wherein:A represents O, S or NR7; wherein R7represents hydrogen, Ci-Cs alkyl or alkyloxycarbonyl;B represents CH or N; andR6represents hydrogen, hydroxy, halo, amino, alkylsulfonyl, aminosulfonyl, cyano, nitro, carboxy, aryl, alkoxy, haloalkyl, alkylamino, aminoalkyl, nitrooxyalkyl or carboxyalkyl.
6. A pharmaceutical composition for use in preventing, treating, and / or lessening acute radiation syndrome in a subject in need thereof, comprising Anethole trithione (AOL), or a structural analog thereof and at least one pharmaceutically acceptable excipient.
7. AOL, or the structural analog thereof, for use according to any one of claims 1 to 5, or the pharmaceutical composition, for use according to claim 6, wherein AOL, the structural analog thereof or the pharmaceutical composition is to be administered before, concomitantly with or after at least one other therapeutic agent.
8. AOL, the structural analog thereof, or the pharmaceutical composition, for use according to claim 7, wherein the at least one other therapeutic agent is selected from the group of: N-acetylcysteine, oltipraz, and Amifostine.
9. AOL or the structural analog thereof, for use according to any one of claims 1 to 5, or the pharmaceutical composition for use according to any one of claims 6 to 8, wherein AOL, the structural analog thereof or the pharmaceutical composition is to be administered before the radiation exposure.
10. AOL or the structural analog thereof, for use according to any one of claims 1 to 5, or the pharmaceutical composition, for use according to any one of claims 6 to 9, wherein AOL, the structural analog thereof or the pharmaceutical composition is to be administered after the radiation exposure.
11. AOL or the structural analog thereof, for use according to any one of claims 1 to 5, or the pharmaceutical composition, for use according to any one of claims 6 to 10, wherein AOL, the structural analog thereof or the pharmaceutical composition is to be administered intravenously.
12. AOL or the structural analog thereof, for use according to any one of claims 1 to 5, or the pharmaceutical composition, for use according to any one of claims 6 to 11, wherein the acute radiation syndrome is selected from (a) hematopoietic acute radiation syndrome, (b) gastrointestinal acute radiation syndrome, (c) cutaneous acute radiation syndrome, (d) central nervous system (CNS) acute radiation syndrome, (e) hematopoietic, gastrointestinal, cutaneous or neurovascular subsyndrome of acute radiation syndrome, (f) cardiovascular (CV) acute radiation syndrome, or (g) pulmonary dysfunction acute radiation syndrome.
